Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial

Phase 3

Completed

Conditions: Hepatitis C

Interventions: Drug: BI 201335 high dose
Drug: BI 201335 low dose

First Posted Date: 2012-04-18

Last Posted Date: 2015-08-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 131

Registration Number: NCT01579474

Locations: 🇯🇵
1220.54.08115 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan
🇯🇵
1220.54.08101 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan
🇯🇵
1220.54.08104 Boehringer Ingelheim Investigational Site, Chuo-ku, Chiba, Japan

and more 21 locations

Drug-drug Interaction of BI 201335 and Microgynon

Phase 1

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: levonorgestrel
Drug: Ethinylestradiol
Drug: BI 201335

First Posted Date: 2012-04-04

Last Posted Date: 2015-08-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT01570244

Locations: 🇩🇪
1220.56.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Placebo
Drug: tiotropium + olodaterol
Drug: tiotropium
Drug: olodaterol
Device: Respimat

First Posted Date: 2012-03-21

Last Posted Date: 2015-07-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 219

Registration Number: NCT01559116

Locations: 🇧🇪
1237.20.32201 Boehringer Ingelheim Investigational Site, Gent, Belgium
🇳🇱
1237.20.31204 Boehringer Ingelheim Investigational Site, Hengelo, Netherlands
🇭🇺
1237.20.36201 Boehringer Ingelheim Investigational Site, Szarvas, Hungary

and more 26 locations

Safety, Tolerability, Pharmacokinetics and Early Pharmacodynamics of Single Rising Oral Doses of BI 1021958 Tablets in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1021958
Drug: Placebo to BI 1021958

First Posted Date: 2012-03-01

Last Posted Date: 2013-10-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 66

Registration Number: NCT01541488

Locations: 🇩🇪
1310.1.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

First in Man Trial of BI 113608

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 113608
Drug: Placebo

First Posted Date: 2012-02-29

Last Posted Date: 2017-01-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 80

Registration Number: NCT01540825

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site, Mannheim, Germany

Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /Metformin

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: linagliptin/metformin(high dose)
Drug: Linagliptin/metformin(low dose)

First Posted Date: 2012-02-28

Last Posted Date: 2013-08-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT01540487

Locations: 🇨🇳
1288.5.86001 Boehringer Ingelheim Investigational Site, Beijing, China

Japan Long-term Safety for Tiotropium Plus Olodaterol

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium + Olodaterol
Drug: Olodaterol
Device: Respimat

First Posted Date: 2012-02-22

Last Posted Date: 2015-07-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 122

Registration Number: NCT01536262

Locations: 🇯🇵
1237.22.81028 Boehringer Ingelheim Investigational Site, Koriyama, Fukushima, Japan
🇯🇵
1237.22.81019 Boehringer Ingelheim Investigational Site, Koto-ku,Tokyo, Japan
🇯🇵
1237.22.81010 Boehringer Ingelheim Investigational Site, Takatsuki, Osaka, Japan

and more 21 locations

Bioavailability of 3 Different Formulations of BI 207127 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 207127

First Posted Date: 2012-02-20

Last Posted Date: 2016-04-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT01535638

Locations: 🇩🇪
1241.26.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium + Olodaterol
Drug: Placebo
Drug: Tiotropium
Drug: Olodaterol
Device: Respimat

First Posted Date: 2012-02-16

Last Posted Date: 2015-09-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 295

Registration Number: NCT01533922

Locations: 🇺🇸
1237.13.01307 Boehringer Ingelheim Investigational Site, Pittsburgh, Pennsylvania, United States
🇺🇸
1237.13.01305 Boehringer Ingelheim Investigational Site, Easley, South Carolina, United States
🇦🇹
1237.13.43303 Boehringer Ingelheim Investigational Site, Linz, Austria

and more 41 locations

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Placebo
Drug: tiotropium + Olodaterol
Drug: Olodaterol
Drug: Tiotropium
Device: Respimat

First Posted Date: 2012-02-16

Last Posted Date: 2015-09-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 291

Registration Number: NCT01533935

Locations: 🇨🇦
1237.14.11404 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada
🇦🇹
1237.14.43402 Boehringer Ingelheim Investigational Site, Grieskirchen, Austria
🇦🇹
1237.14.43401 Boehringer Ingelheim Investigational Site, Neumarkt am Wallersee, Austria

and more 30 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy